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Abstract: The Ikaros transcription factor is crucial for many aspects of hematopoiesis. Loss of function mutations in 
IKZF1, the gene encoding Ikaros, have been implicated in adult and pediatric B cell acute lymphoblastic leukemia 
(B-ALL). These mutations result in haploinsufficiency of the Ikaros gene in approximately half of the cases. The 
remaining cases contain more severe or compound mutations that lead to the generation of dominant-negative 
proteins or complete loss of function. All IKZF1 mutations are associated with a poor prognosis. Here we review the 
current genetic, clinical and mechanistic evidence for the role of Ikaros as a tumor suppressor in B-ALL.
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From T-ALL to center stage in B-ALL
Ikaros is a zinc finger transcription factor 
encoded by the IKZF1 gene. First characterized 
as a protein that binds to regulatory elements 
in the genes encoding CD3δ and deoxynucleoti-
dyl terminal transferase in T lymphocytes [1, 2], 
knock-out studies in animals have revealed a 
wide-ranging role for Ikaros in many aspects of 
hematopoiesis. Ikaros null mice show a pro-
found reduction in hematopoietic stem cell 
activity, lack numerous hematopoietic cell 
types such as B cells, NK cells and dendritic 
cells, are defective in erythropoiesis and show 
a differentiation bias towards the CD4+ T cell 
lineage in the thymus [3-8]. At the molecular 
level, Ikaros both represses and activates gene 
transcription by binding to target sequences 
containing the core TGGGAA sequence, and it 
interacts with chromatin remodeling complexes 
to modulate gene expression [9-11].
Mouse studies also revealed Ikaros to be a 
tumor suppressor in T cells. Indeed, mice het-
erozygous for a dominant-negative (dn) muta-
tion of Ikzf1, or homozygous for a knock-down 
Ikzf1 mutation, develop T cell lymphomas/leu-
kemias with 100% penetrance [12-15]. Other 
studies have confirmed the prominent status of 
Ikaros as a major tumor suppressor in T cells in 
the mouse (see [16] for review). These results 
prompted several teams to investigate if Ikaros 
mutations were implicated in human T cell 
malignancies. However, Ikaros defects are rare 
in T cell acute lymphoblastic leukemias (T-ALL) 
and are observed in approximately 5% of cases 
[17-19].
Interestingly, Ikaros mutations are frequent in 
B-ALL. These studies can be grossly divided 
into those done before, versus those done 
after, the age of pan-genomic technology. Early 
results, based primarily on RT-PCR analysis of 
the IKZF1 coding sequence, revealed the pres-
ence of Ik6, a dn Ikaros isoform, in a subset of 
pediatric and adult B-ALL [20-24]. Nakase et al 
and Tonnelle et al reported that Ik6 is detected 
in ~30% of adult B-ALL, and is prevalent in 
those presenting the t(9; 22) translocation that 
generates the BCR-ABL fusion oncoprotein [20, 
22]. Ik6 is also associated with BCR-ABL posi-
tive chronic myeloid leukemia (CML) cells in 
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blast crisis [25]. As Ik6 expression is accompa-
nied by the appearance of novel restriction 
fragments in Southern blot analyses of the 
IKZF1 locus, it was suggested that genomic 
rearrangements occur in this region [20, 25]. 
Other mechanisms such as alternative splicing 
of IKZF1 transcripts in response to BCR-ABL 
signaling were also proposed [26]. With the 
advent of large-scale comparative genomic 
hybridization (CGH) technology using high-den-
sity microarrays, it finally became clear that 
IKZF1 is subject to frequent somatic muta-
tions/deletions in B-ALL [27-30]. These studies 
showed that 15-20% of pediatric B-ALL and 
>75% of BCR-ABL positive B-ALL are affected 
by genomic deletions in the IKZF1 locus (Table 
1). Fewer studies have investigated adult B-ALL, 
but available data suggest that IKZF1 muta-
tions might occur at an even higher frequency 
in adults (close to 50%, Table 1) [31, 32]. The 
deletions fall into several categories (see 
below), with one being an intragenic deletion of 
IKZF1 exons 4-7. Transcription from these 
alleles produces Ikaros transcripts lacking 
exons 4-7 and corresponding 
to Ik6. In addition, Mullighan 
et al showed an absolute cor-
relation between exon 4-7 
deletions, and Ik6 transcripts 
and proteins [29]. Thus 
genomic deletion is the domi-
nant mechanism behind the 
synthesis of dn Ik6 isoforms 
in B-ALL. Collectively, these 
studies identify Ikaros loss of 
function as a recurrent anom-
aly in human B-ALL.
The genetics of Ikaros loss of 
function in B-ALL
Nature of somatic IKZF1 
mutations in B-ALL
The human IKZF1 locus spans 
over 120 kilobases (kb) on 
chromosome 7p12.2, and 
comprises 8 exons. Mutations 
in this locus in B-ALL can be 
grouped into 3 main catego-
ries (Figure 1A). The first cor-
responds to monosomy 7 or 
large deletions of the 7p arm, 
features found in ~4% of all 
B-ALL [33]. This defect is 
always associated with the complete loss of 
one IKZF1 allele. As none of the other known 
tumor suppressors in B-ALL is located on chro-
mosome 7, it is reasonable to assume that loss 
of Ikaros might be a driving force in selecting for 
this anomaly. The second category consists of 
deletions of 15-200 kb which are restricted to 
the IKZF1 gene. The most common deletion is 
one of 50.7 kb that comprises exons 4 to 7 (Δ4-
7). The 5’ and 3’ breakpoints are highly con-
served and are flanked by recombination signal 
sequences (RSS), suggesting that this deletion 
is mediated by off-target effects of the recombi-
nation activating gene (RAG) proteins during 
VDJ recombination in B cell progenitors [29, 
30]. Δ4-7 deletions lead to in-frame splicing of 
exon 3 to exon 8, and the synthesis of Ik6. A 
second common deletion comprises exons 2-7 
(Δ2-7). These deletions have the same 3’ break-
point as the Δ4-7 deletion but more variable 5’ 
breakpoints [30, 34]. They are also likely to be 
mediated by the RAG machinery, as the break-
points are flanked by RSS motifs. Δ2-7 dele-
tions probably lead to null alleles, since exon 2 
Figure 1. Distribution of the various types of mutations in B-ALL cases with 
IKZF1 defects. A. Distribution of the genetic defects in B-ALL cases with 
IKZF1 abnormalities. Numbers are estimates and derived from compiled 
data from the studies of Mullighan et al. and Dupuis et al [31, 35]. B. Distri-
bution of functional classes of mutations. Data are derived from the study 
by Dupuis et al [31].
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encodes the initiation ATG. In addition, other 
types of deletions have been reported. These 
delete the non-coding exon 1 and various 
lengths of 5’ sequences, and other combina-
tions of coding exons, like exons 2-8 [30, 31, 
34]. All of the deletions are likely to result in null 
mutations. Finally the last category corre-
sponds to point mutations [35-37], usually 
frameshift mutations leading to 
premature stop codons; they 
account for 11 of the combined 
97 IKZF1 mutations (~10%) 
reported in these studies. One 
case is a point mutation that 
results in a G to S amino acid 
change in the second zinc finger 
of the DNA binding domain 
(DBD) of Ikaros [35]. Point muta-
tions affecting the DBD are fre-
quent spontaneous mutations 
in murine T-ALL where they are 
predicted to impair Ikaros func-
tion (see [16] for review). Other 
studies, however, have failed to 
detect point mutations in large 
B-ALL cohorts [29, 30, 38]. 
These discrepancies may reflect 
technical issues, or an overall 
low incidence of IKZF1 point 
mutations if they are less fre-
quent in BCR-ABL positive 
cases (the focus of 2 of the neg-
ative studies) [29, 30]. It is note-
worthy that the highest frequen-
cy of point mutations (3 out of 
12 IKZF1 mutations) was found 
using deep sequencing of 
genomic DNA and mRNA, which 
seems to provide the most 
accurate data [37]. Thus, the 
true frequency of IKZF1 point 
mutations in B-ALL remains 
uncertain and must be reas-
sessed with deep sequencing 
techniques on large cohorts of 
patients.
Functional classes of IKZF1 
mutations
Approximately 55% of B-ALL 
with IKZF1 mutations exhibit a 
monoallelic null mutation. 
These mutations lead to haplo-
insufficiency, with reduced pro-
Figure 2. Three functional classes of IKZF1 mutations in B-ALL are associ-
ated with distinct quantities and localizations of Ikaros proteins. Immuno-
fluorescence detection of Ikaros proteins in B-ALL cells from WT, haplo-
insufficient (Δ2-7 deletion), dominant-negative (Δ4-7 deletion) or biallelic 
null mutations, as indicated.
tein levels of Ikaros as detected by Western 
blot and immunofluorescence (Figure 2) [31]. 
Δ4-7 deletions account for ~33% of IKZF1 
mutations. These deletions lead to the produc-
tion of the Ik6 isoform, which is synthesized 
abundantly and localized in the cytoplasm due 
to the loss of the DBD and nuclear localization 
sequences (Figure 2) [21, 24, 31]. Because Ik6 
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can dimerize with wild type (WT) Ikaros proteins 
synthesized from the intact allele, it is thought 
to exert a dominant-negative effect by seques-
tering normal proteins in the cytoplasm, as well 
as the related Aiolos, Helios or Eos proteins. 
Indeed, a similar deletion in the mouse leads to 
a phenotype that is more severe than a null 
mutation [39]. About 12% of B-ALL with IKZF1 
mutations have biallelic deletions [29-31, 37]. 
Most of these correspond to 2 null alleles which 
lead to the complete absence of Ikaros pro-
teins (Figure 2) [29, 31]. Thus B-ALL with IKZF1 
mutations can be subdivided into 3 functional 
categories with haploinsufficient, dominant-
negative and null Ikaros phenotypes (Figure 2). 
The occurrence of biallelic null mutations indi-
cates that some leukemic cells that have lost 
one IKZF1 allele will gain a selective advantage 
by losing the second allele. Indeed, some B-ALL 
exhibit both a null and a Δ4-7 deletion [29-31], 
suggesting that the Δ4-7 deletion is acquired to 
further reduce Ikaros activity from a haploin-
sufficient state.
It is currently unclear if different classes of 
mutations are associated with different molec-
ular signatures or clinical states. As the loss of 
one or two IKZF1 alleles results in dramatically 
different consequences in the mouse, it is likely 
that haploinsufficient and severe (Δ4-7 dele-
tions or biallelic mutations) mutations will also 
be associated with distinct phenotypes. Various 
studies have indicated that BCR-ABL positive 
B-ALL predominantly exhibit severe IKZF1 
mutations. These mutations account for 70%, 
65% and 59% of the IKZF1 mutations exam-
ined by Dupuis et al, Mullighan et al, and 
Iacobucci et al, respectively [29-31]. They are in 
agreement with earlier studies that reported 
high frequencies of Ik6 mRNA expression in 
BCR-ABL positive B-ALL [22, 24]. In contrast, 
haploinsufficiency is predominant in BCR-ABL 
negative B-ALL (72% of the IKZF1 mutations in 
the adult and pediatric cases studied by Dupuis 
et al [31], and 57% of the IKZF1 mutations in 
the high risk pediatric cases studied by 
Mullighan et al [35]). These observations sug-
gest that the selective pressure to acquire 
severe Ikaros mutations is higher in BCR-ABL 
positive B-ALL than other subtypes. More stud-
ies are required to determine if there is a func-
tional basis for this difference, and if distinct 
classes of Ikaros mutations are correlated with 
other clinical features.
IKZF1 mutations as secondary hits during B-
ALL progression?
Recent studies have suggested that IKZF1 
mutations may occur as secondary mutations 
in B-ALL. Cazzaniga et al reported cases of 
B-ALL that developed in two pairs of monozy-
gotic twins [40]. In the first pair, both twins 
developed B-ALL that exhibited the same BCR-
ABL rearrangement, but only one had a IKZF1 
deletion. In the second pair, one twin developed 
a leukemia that exhibited a BCR-ABL fusion 
gene and a loss of IKZF1. The other twin also 
had cells with the same BCR-ABL fusion but no 
IKZF1 deletion, and was healthy. In these 
cases, the t(9; 22) translocation was the initiat-
ing event, while the IKZF1 deletion was acquired 
secondarily. Dupuis et al identified a BCR-ABL 
positive B-ALL with both a complete deletion of 
the IKZF1 gene and a Δ4-7 deletion at diagno-
sis, but only the complete deletion at relapse 
[31], suggesting that 2 leukemic clones existed 
at diagnosis, and only one remained at relapse. 
Cayé et al employed multiplex qPCR to detect 
common IKZF1 intragenic rearrangements in a 
cohort of B-ALL [34], and identified 4 cases 
with at least two IKZF1 rearrangements at the 
subclonal level. 15 other cases had a single 
IKZF1 rearrangement that was present in only a 
fraction of the leukemic cells (1-20%). These 
data indicate that IKZF1 mutations can arise as 
secondary mutations during disease progres-
sion, and that independent mutations can be 
selected for in different clones. IKZF1 muta-
tions can also be acquired late, as some cases 
have been reported where the IKZF1 mutation 
was not detected at diagnosis but only at 
relapse [36, 41, 42]. An important question is 
whether IKZF1 mutations are oncogenic alone 
or only in synergy with other mutations. In this 
regard, mice haploinsufficient for Ikzf1 in their 
germline never develop B-ALL on their own, but 
those heterozygous for Ikzf1 display accelerat-
ed B cell leukemogenesis in the presence of a 
Bcr-Abl transgene [43]. Reconstitution of the 
phylogenic mutational tree will be required to 
define how IKZF1 mutations fit into the genetic 
hierarchy of B-ALL [44].
Inherited polymorphisms of IKZF1 predispose 
to B-ALL
In addition to somatic mutations, polymor-
phisms of the IKZF1 locus significantly predis-
pose to childhood B-ALL according to 2 
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genome-wide association studies (GWAS), sug-
gesting that inherited variations in the IKZF1 
gene may promote early B-ALL. Papaemmanuil 
et al found that the “C” variant of SNP 
rs4132601 is a risk factor for B-ALL [45]. This 
SNP is located in exon 8, in the sequence 
encoding the 3’ untranslated region of Ikaros, 
and may interfere with mRNA stability. Indeed, 
the C variant is associated with reduced Ikaros 
mRNA levels in blood leucocytes. The correla-
tion between this variant and pediatric B-ALL 
was independently confirmed in cohorts of 
patients from Poland [46], and from Germany 
and the United Kingdom [47]. In all 3 studies, 
heterozygosity for the risk allele is associated 
with increased ALL frequency, and the risk 
increases with homozygosity. Another GWAS 
study by Trevino et al identified a second SNP 
(rs11978267) located in intron 7 of IKZF1 [48]. 
The “G” variant of this SNP is linked to an 
increased predisposition to ALL, with an 
increased risk from the heterozygous to the 
homozygous condition. The relevance of this 
SNP was also investigated by Ross et al in 
infant ALL and acute myeloid leukemia (AML) 
[49]. These authors found that the G variant 
significantly increases the risk for ALL lacking 
MLL rearrangements, but not for ALL with MLL 
rearrangements. Interestingly, the G variant 
also increases the risk for AML. Why a single 
nucleotide change in an intronic region should 
increase the risk of leukemia development 
remains obscure. It is noteworthy, however, 
that the location of the rs11978267 SNP bor-
ders a predicted enhancer in the human 
GM12878 B lymphoblastoid cell line, but not in 
non-B cell lines, as delineated by the presence 
of mono- or tri-methylated lysine 4 of histone 
H3 in this region (data from ENCODE; Figure 3). 
It is therefore possible that this sequence varia-
tion modulates the activity of a regulatory ele-
ment important for Ikaros expression in B cells.
Clinical significance of IKZF1 mutations
Association with genetic defects that activate 
the JAK-STAT pathway
As noted, IKZF1 mutations strongly associate 
with the BCR-ABL fusion oncogene. This is true 
both for B-ALL and for lymphoid blast crisis 
CML where IKZF1 mutations are frequently 
detected [25, 29, 30, 50, 51], suggesting that 
Ikaros deficiency plays a role in modulating the 
oncogenic activity of the BCR-ABL kinase.
Figure 3. Localization of SNPs associated with increased susceptibility for childhood B-ALL and chromatin features 
of active regulatory elements in the B lymphoblastoid GM12878 and erythro-myeloid K562 cell lines. ChIP-seq data 
for mono- and tri-methylated lysine 4 of histone H3 (H3K4me1 and H3K4me3, respectively) are from publicly avail-
able tracks from the ENCODE consortium. The rs11978267 SNP borders a region specifically associated with active 
chromatin marks in the GM12878 cells.
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The potent synergy between IKZF1 loss of func-
tion and BCR-ABL was recently demonstrated 
in a mouse model of B-ALL. Deletion of a single 
allele of Ikzf1 in mice expressing a BCR-ABL 
transgene leads to a dramatic acceleration of 
B-ALL development, with a decrease in median 
survival time from 14.7 to 5.7 weeks [43]. 
Further, Ikzf1 haploinsufficiency is associated 
with a polyclonal disease, while leukemias that 
develop in mice with WT Ikzf1 alleles are mono- 
or oligoclonal. Importantly, leukemic cells from 
the double mutant mice retain the intact Ikzf1 
allele and express Ikaros proteins at about 50% 
of WT levels. Thus a reduction in Ikaros activity 
is sufficient to accelerate B-ALL development.
Interestingly, IKZF1 mutations are also frequent 
in BCR-ABL negative leukemias that share a 
similar gene expression signature with BCR-
ABL positive B-ALL [52]. A point in common may 
be the JAK-STAT pathway. BCR-ABL signaling 
activates the JAK-STAT pathway [53], as do 
amplifications of CRFL2 (which encodes the 
receptor for the cytokine TSLP), activating 
mutations of JAK2 or other types of rearrange-
ments/mutations involving genes encoding 
receptors that signal through this pathway, like 
IL7R, FLT3 and PDGFR [37, 54, 55]. These data 
suggest that Ikaros deficiency may synergize 
with JAK-STAT activation in the presence or 
absence of BCR-ABL.
IKZF1 mutations are predictive of a poor 
prognosis
IKZF1 mutations are associated with a poor 
prognosis in terms of overall survival and fre-
quency of relapse. This has been studied most-
ly in pediatric B-ALL, but also appears to be 
true for adult B-ALL (Table 1) [31, 32, 35, 36, 
Table 1. Summary of recent studies that addressed Ikaros loss of function in B-ALL
Study Patient cohort Main results
Mullighan 
2008 [29]
43 Pediatric BCR-ABL positive B-ALL • IKZF1 deletions in 84% of cases
• IKZF1 mutations frequent in lymphoid blast crisis of 
CML patients
Mullighan 
2009 [35]
• 221 pediatric high risk BCR-ABL 
negative B-ALL
• 258 pediatric B-ALL
• IKZF1 mutations in 28.6% of high risk cases and 24.8% 
of validation cohort
• IKZF1 mutations are predictive of adverse prognosis
Iacobucci 
2009 [30]
106 Adult BCR-ABL positive B-ALL • IKZF1 mutations in 75% of patients
• IKZF1 mutations in 66% of lymphoid blast crisis of CML 
patients
Kuiper 2010 
[36]
• 34 selected diagnosis/ relapse 
pairs of pediatric B-ALL
• 131 unselected pediatric B-ALL 
• 18/131 mutations in the unselected cohort (13.7%)
• 13/34 IKZF1 mutations in the relapse prone cohort
• 2 patients with IKZF1 mutations that appeared at 
relapse
Martinelli 
2009 [56]
83 BCR-ABL positive adult patients • 63% with IKZF1 deletions
• shorter disease-free survival of patients with IKZF1 
mutations
Dupuis 2012 
[31]
139 unselected adult (46) and pediat-
ric (93) B-ALL 
• IKZF1 deletions in 52% of adult and 27% of pediatric 
patients
• biallelic deletions in 15% of patients with IKZF1 dele-
tions
• several cases of biclonal deletions
• IKZF1 deletions are associated with adverse prognosis 
in adult BCR-ABL negative patients
Cayé 2012 
[34]
• 60 BCR-ABL positive pediatric B-ALL
• 512 BCR-ABL negative pediatric 
B-ALL
• 75% of IKZF1 deletions in BCR-ABL positive B-ALL
• 16% of IKZF1 deletions in BCR-ABL negative B-ALL
• multiple cases of subclonal IKZF1 deletions
Harvey 2010 
[54]
207 high risk pediatric B-ALL • 30% of IKZF1 mutations
• Strong association with JAK1 or JAK2 mutations and 
CRLF2 rearrangements
Mi 2012 
[32]
• 203 unselected adult B-ALL
• 379 unselected pediatric B-ALL
• 56 pediatric cases with the Δ4-7 deletion (14.7%)
• 64 adult cases with the Δ4-7 deletion (31.3%)
• Other types of IKZF1 mutations not studied
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56-58]. In children, IKZF1 mutations are a bet-
ter predictor of relapse than other genetic 
defects (ie. EBF1 or PAX5 mutations), or the 
conventional classification based on clinical 
and cytogenetic criteria [35]. Interestingly, the 
combination of IKZF1 mutations and minimal 
residual disease (MRD) status is a better pre-
dictor of relapse than either marker alone [59], 
suggesting that risk stratification may be 
improved by comparing IKZF1 status with other 
criteria of adverse prognosis. In this regard, we 
have observed that IKZF1 deficiency appears to 
synergize with a lack of IgH rearrangements, as 
these parameters point to a very pejorative 
prognosis (Figure 4). These results were 
obtained using multivariate analysis to identify 
clinical parameters in a cohort of 139 adult and 
pediatric B-ALL, and must be confirmed on 
more patients. Collectively, these studies sug-
gest that loss of IKZF1 may synergize with other 
biological or clinical features to define subsets 
of particularly aggressive leukemias.
Ikaros mutations to assess MRD
Two groups have proposed that IKZF1 muta-
tions, when detected at diagnosis, may be reli-
able markers to follow MRD [34, 60]. The strong 
association of IKZF1 deletions with aggressive 
leukemias and relapse, as well as the relatively 
well conserved breakpoints of the deletions, 
provide a strong case using IKZF1 rearrange-
ments as MRD markers. Venn et al used qPCR 
to quantify the Δ4-6 deletion, while Cayé et al 
employed multiplex qPCR to simultaneously 
detect the various IKZF1 breakpoints that may 
occur in distinct leukemic subclones. Both 
studies showed that IKZF1 deletions can be 
sensitive markers to monitor leukemias in 
remission. It should be noted, however, that 
some leukemias may escape detection using 
these methods, as was true for a leukemia with 
biclonal IKZF1 mutations (chromosome 7 rear-
rangement, Δ4-7 deletion) at diagnosis and 
which lost the Δ4-7 deletion at relapse (see 
above) [31].
The challenge of identifying IKZF1 mutations 
at diagnosis
The strong association of IKZF1 mutations with 
a poor prognosis has prompted calls for IKZF1 
screening at diagnosis [61]. This raises the 
question of which method to use. Multiplex 
Ligation Probe-dependent Amplification (MLPA) 
is powerful for detecting genomic deletions 
[62], but it cannot distinguish between mono- 
and biallelic deletions, or deletions that affect 
leukemic subclones [31]. This conclusion was 
also reached by Cayé et al who found that MLPA 
did not detect IKZF1 rearrangements in 13 of 
82 leukemias (15%) with IKZF1 deletions [34]. 
We have developed PCR-based methods to 
analyze Δ4-7 and larger deletions [31], but 
Figure 4. Overall survival curves of patients from the cohort of 136 adult and pediatric patients described by Dupuis 
et al [31], according to their IKZF1 status and IgH rearrangement (as determined by the Biomed2 protocol). Statisti-
cal significance of the differences among the 4 groups of patients was estimated using a Cox Model. The number 
of patients in the IgH-neg/IKZF1-deleted, IgH-pos/IKZF1-deleted, IgH-neg/IKZF1-WT and IgH-pos/IKZF1-WT were 
respectively 7, 42, 9 and 78. The group of patients (3 pediatric and 4 adults) who had IKZF1 deletions and lacked 
IgH rearrangements had a particularly poor survival, suggesting a synergistic predictive value of these two features 
(note that only 6 IgH-neg/IKZF1-deleted patients could be included in the overall survival analysis as the fate of one 
patient that had relapsed after 178 days is unknown).
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these miss unconventional deletions affecting 
the 5’ IKZF1 region. The direct multiplex PCR 
amplification developed by Cayé et al to detect 
various IKZF1 breakpoints is very sensitive and 
can detect IKZF1 mutations in even minor leu-
kemic subclones [34], but this method will not 
detect 5’ deletions. Further, no method has 
been developed that can identify point muta-
tions. Thus the development of a robust and 
rapid method for the identification of IKZF1 
mutations remains a challenge.
Possible functions of IKZF1 mutations in B 
cell leukemogenesis
Maintenance of a stem cell phenotype
The molecular events affected by the loss of 
Ikaros remain poorly understood. Gene expres-
sion signatures associated with loss of IKZF1 in 
pediatric and adult B-ALL have revealed an 
overexpression of genes indicative of a stem 
cell phenotype [35, 63]. This possibility was 
first proposed by Tonnelle et al who found that 
Ik6 expressing adult B-ALL show higher levels 
of CD34 [22]. In animal models, Ng et al have 
reported that certain stem cell genes are less 
efficiently silenced in lymphoid progenitors 
from Ikaros null mice [8]. It remains to be seen 
if Ikaros is directly involved in the suppression 
of a stem cell signature. Thus Ikaros deficiency 
might lead to the persistence or activation of a 
stem cell gene expression program which may 
favor the self-renewal or formation of leukemic 
stem cells.
Blocking B cell differentiation
Another role for Ikaros deficiency may be to 
block B cell differentiation. In the mouse, Ikaros 
is required for B cell commitment, as Ikaros null 
mice lack B cells [3]. In addition, Ikaros is need-
ed during B cell differentiation, as animals 
expressing low levels of Ikaros show a partial 
block in the transition between the pro- and 
pre-B cell stage [64]. Ikaros binds to regulatory 
elements in the IgH locus and is required for 
the rearrangement of the heavy chain of the B 
cell receptor (BCR) and pre-BCR [65-67]. Ikaros 
is also important for silencing the Igll1 gene, 
which encodes the Lambda 5 surrogate light 
chain of the pre-BCR [68-70]. These results 
suggest that Ikaros plays a role in regulating 
both the up- and downregulation of the pre-
BCR. Other studies have suggested that Ikaros 
functions downstream of the pre-BCR, by con-
tributing to the cell cycle arrest induced by pre-
BCR signaling in pro-B cells [71], through down-
regulation of c-Myc [72], and induction of kappa 
light chain expression [67]. Thus, Ikaros 
appears to be a key regulator of the pre-BCR 
checkpoint during B cell differentiation.
Regulation of JAK-STAT signaling
As discussed, IKZF1 mutations are prevalent in 
leukemias with activated JAK-STAT signaling, 
suggesting that Ikaros may repress the activity 
of this pathway. How this is achieved remains to 
be determined. Ikaros has been shown to 
antagonize the Notch pathway in T cells as well 
as Ebf1 in B cells [69, 73]. Since downregula-
tion of Stat5-mediated gene expression is cru-
cial for B cell differentiation after the pro-B cell 
stage [74], Ikaros repression at this juncture 
might explain why Ikaros is important for the 
pro- to pre-B cell transition. Thus, it will be 
important to study if and how Ikaros modulates 
STAT5-mediated target gene regulation.
Conclusion and future challenges
It is now clear that IKZF1 loss of function muta-
tions are important genetic events associated 
with aggressive B cell leukemias. Several out-
standing issues need to be clarified in the 
future. It will be important to understand the 
sequence of events leading to Ikaros loss of 
function. In particular, the frequency of point 
mutations as well as the possibility of epigene-
tic, transcriptional or post-transcriptional 
silencing need to be addressed. It will also be 
important to determine if B-ALL with severe 
Ikaros deficiencies (eg. loss of both alleles or 
expression of dn proteins) exhibit distinct clini-
cal and molecular features compared with 
those haploinsufficient for IKZF1. Standardized 
diagnostic tools to genotype IKZF1 mutations 
need to be defined. Finally, the mechanism of 
tumor suppression by Ikaros needs to be better 
understood. The integration of fundamental 
and clinical studies will be needed for these 
aims to be achieved.
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